Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

The identification of certain genomic alterations ( , , , ) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancers 2018-03, Vol.10 (3), p.70
Hauptverfasser:	Hofman, Véronique, Lassalle, Sandra, Bence, Coraline, Long-Mira, Elodie, Nahon-Estève, Sacha, Heeke, Simon, Lespinet-Fabre, Virginie, Butori, Catherine, Ilié, Marius, Hofman, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Epidermal growth factor receptors Genomes Immunohistochemistry Lung cancer Metastases Metastasis Patients PD-L1 protein Review Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!